Molecular pathology of lung cancers

Molecular Surgical Pathology

Volumn 9781461449003, Issue , 2013, Pages 83-94

  Sholl, Lynette M ^a   Lindeman, Neal I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949176348     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4900-3_5     Document Type: Chapter

References (66)

1. http://seer.cancer.gov/statfacts/html/lungb.html
2. Bergethon K, Shaw AT, Ignatius Ou SH, et al.ROS1 rearrangements de fi ne a unique molecular class of lung cancers.J Clin Oncol.2012;30:863-70.
3. Brevet M, Arcila M, Ladanyi M.Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies speci fi c to the two major forms of mutant EGFR.J Mol Diagn.2010;12:169-76.
4. Cappuzzo F, Hirsch FR, Rossi E, et al.Epidermal growth factor receptor gene and protein and ge fi tinib sensitivity in nonsmall-cell lung cancer.J Natl Cancer Inst.2005;97:643-55.
5. Cappuzzo F, Ligorio C, Janne PA, et al.Prospective study of ge fi tinib in epidermal growth factor receptor fl uorescence in situ hybridization-positive/phosphoakt-positive or never smoker patients with advanced nonsmall-cell lung cancer: the ONCOBELL trial.J Clin Oncol.2007;25:2248-55.
6. Carretero J, Shimamura T, Rikova K, et al.Integrative genomic and proteomic analyses identify targets for Lkb1-de fi cient metastatic lung tumors.Cancer Cell.2010;17:547-59.
7. Cetin K, Ettinger DS, Hei YJ, et al.Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the surveillance, epidemiology and end results program.Clin Epidemiol.2011;3:139-48.
8. Clark GM, Zborowski DM, Culbertson JL, et al.Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced nonsmall cell lung cancer for treatment with erlotinib.J Thorac Oncol.2006;1:837-46.
9. Dacic S, Flanagan M, Cieply K, et al.Signi fi cance of EGFR protein expression and gene ampli fi cation in nonsmall cell lung carcinoma.Am J Clin Pathol.2006;125:860-5.
10. Dutt A, Ramos AH, Hammerman PS, et al.Inhibitorsensitive FGFR1 ampli fi cation in human nonsmall cell lung cancer.PLoS One.2011;6:e20351.
11. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A, editors.AJCC cancer staging manual.7th ed.New York: Springer; 2010.
12. Engelman JA, Zejnullahu K, Mitsudomi T, et al.MET ampli fi cation leads to ge fi tinib resistance in lung cancer by activating ERBB3 signaling.Science.2007;316: 1039-43.
13. Ferguson KM.Structure-based view of epidermal growth factor receptor regulation.Annu Rev Biophys.2008;37:353-73.
14. Greenman C, Stephens P, Smith R, et al.Patterns of somatic mutation in human cancer genomes.Nature.2007;446:153-8.
15. Hammerman P, Sos M, Ramos A, et al.Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.Cancer Discov.2011;1:78-89.
16. Hirsch FR, Varella-Garcia M, Bunn Jr PA, et al.Molecular predictors of outcome with ge fi tinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer.J Clin Oncol.2006;24:5034-42.
17. Hirsch FR, Varella-Garcia M, McCoy J, et al.Increased epidermal growth factor receptor gene copy number detected by fl uorescence in situ hybridization associates with increased sensitivity to ge fi tinib in patients with bronchioloalveolar carcinoma subtypes: a southwest oncology group study.J Clin Oncol.2005;23:6838-45.
18. Huang SF, Liu HP, Li LH, et al.High frequency of epidermal growth factor receptor mutations with complex patterns in nonsmall cell lung cancers related to ge fi tinib responsiveness in Taiwan.Clin Cancer Res.2004;10:8195-203.
19. Jackman DM, Yeap BY, Sequist LV, et al.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in nonsmall cell lung cancer patients treated with ge fi tinib or erlotinib.Clin Cancer Res.2006;12:3908-14.
20. Janne PA, Borras AM, Kuang Y, et al.A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.Clin Cancer Res.2006; 12:751-8.
21. Ji H, Li D, Chen L, et al.The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.Cancer Cell.2006;9:485-95.
22. Kranenburg O.The KRAS oncogene: past, present, and future.Biochim Biophys Acta.2005;1756:81-2.
23. Kumar A, Petri ET, Halmos B, et al.Structure and clinical relevance of the epidermal growth factor receptor in human cancer.J Clin Oncol.2008;26:1742-51.
24. Kwak EL, Bang YJ, Camidge DR, et al.Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer.N Engl J Med.2010;363:1693-703.
25. Li AR, Chitale D, Riely GJ, et al.EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.J Mol Diagn.2008; 10:242-8.
26. Maemondo M, Inoue A, Kobayashi K, et al.Ge fi tinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR.N Engl J Med.2010;362:2380-8.
27. Mahoney CL, Choudhury B, Davies H, et al.LKB1/ KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.Br J Cancer.2009;100: 370-5.
28. McLeer-Florin A, Moro-Sibilot D, Melis A, et al.Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.J Thorac Oncol.2012;7:348-54.
29. Mino-Kenudson M, Chirieac LR, Law K, et al.A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.Clin Cancer Res.2010;16:1561-71.
30. Mok TS, Wu YL, Thongprasert S, et al.Ge fi tinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med.2009;361:947-57.
31. Motoi N, Szoke J, Riely GJ, et al.Lung adenocarcinoma: modi fi cation of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.Am J Surg Pathol.2008;32:810-27.
32. Murray S, Dahabreh IJ, Linardou H, et al.Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in nonsmall cell lung cancer: an analytical database.J Thorac Oncol.2008;3:832-9.
33. Murren J, Turrisi A, Pass H.Small cell lung cancer.In: DeVita V, Hellman S, Rosenberg S, editors.Cancer: principles and practice of oncology.7th ed.Philadelphia: Lippincott, Williams & Wilkins; 2005.p.810.
34. Ohsaki Y, Tanno S, Fujita Y, et al.Epidermal growth factor receptor expression correlates with poor prognosis in nonsmall cell lung cancer patients with p53 overexpression.Oncol Rep.2000;7:603-7.
35. Ou SH, Bazhenova L, Camidge DR, et al.Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with nonsmall cell lung cancer.J Thorac Oncol.2010;5:2044-6.
36. Pao W, Miller V, Zakowski M, et al.EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to ge fi tinib and erlotinib.Proc Natl Acad Sci USA.2004;101:13306-11.
37. Parra HS, Cavina R, Latteri F, et al.Analysis of epidermal growth factor receptor expression as a predictive factor for response to ge fi tinib ('iressa', ZD1839) in nonsmall-cell lung cancer.Br J Cancer.2004;91: 208-12.
38. Pollack JR, Perou CM, Alizadeh AA, et al.Genome-wide analysis of DNA copy-number changes using cDNA microarrays.Nat Genet.1999;23:41-6.
39. Rodig SJ, Mino-Kenudson M, Dacic S, et al.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Clin Cancer Res.2009;15:5216-23.
40. Sanchez-Cespedes M, Parrella P, Esteller M, et al.Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.Cancer Res.2002; 62:3659-62.
41. Schubbert S, Shannon K, Bollag G.Hyperactive ras in developmental disorders and cancer.Nat Rev Cancer.2007;7:295-308.
42. Sequist LV, Waltman BA, Dias-Santagata D, et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Sci Transl Med.2011;3:75ra26.
43. Sharma SV, Bell DW, Settleman J, et al.Epidermal growth factor receptor mutations in lung cancer.Nat Rev Cancer.2007;7:169-81.
44. Shaw AT, Solomon B.Targeting anaplastic lymphoma kinase in lung cancer.Clin Cancer Res.2011;17: 2081-6.
45. Shaw AT, Yeap BY, Mino-Kenudson M, et al.Clinical features and outcome of patients with nonsmall-cell lung cancer who harbor EML4-ALK.J Clin Oncol.2009;27:4247-53.
46. Shaw AT, Yeap BY, Solomon BJ, et al.Effect of crizotinib on overall survival in patients with advanced nonsmall-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.Lancet Oncol.2011;12:1004-12.
47. Shigematsu H, Lin L, Takahashi T, et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.J Natl Cancer Inst.2005;97:339-46.
48. Sholl LM, John Iafrate A, Chou YP, et al.Validation of chromogenic in situ hybridization for detection of EGFR copy number ampli fi cation in nonsmall cell lung carcinoma.Mod Pathol.2007;20:1028-35.
49. Sholl LM, Xiao Y, Joshi V, et al.EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in nonsmall cell lung carcinoma than FISH, CISH, and immunohistochemistry.Am J Clin Pathol.2010;133: 922-34.
50. Sholl LM, Yeap BY, Iafrate AJ, et al.Lung adenocarcinoma with EGFR ampli fi cation has distinct clinicopathologic and molecular features in never-smokers.Cancer Res.2009;69:8341-8.
51. Slamon DJ, Leyland-Jones B, Shak S, et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med.2001;344:783-92.
52. Soh J, Toyooka S, Ichihara S, et al.Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung.J Thorac Oncol.2008;3:340-7.
53. Sordella R, Bell DW, Haber DA, et al.Ge fi tinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.Science.2004;305:1163-7.
54. Takano T, Ohe Y, Sakamoto H, et al.Epidermal growth factor receptor gene mutations and increased copy numbers predict ge fi tinib sensitivity in patients with recurrent nonsmall-cell lung cancer.J Clin Oncol.2005;23:6829-37.
55. Tokumo M, Toyooka S, Kiura K, et al.The relationship between epidermal growth factor receptor mutations and clinicopathologic features in nonsmall cell lung cancers.Clin Cancer Res.2005;11:1167-73.
56. Toyooka S, Takano T, Kosaka T, et al.Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of ge fi tinib-treated patients with lung adenocarcinoma.Cancer Sci.2008;99:303-8.
57. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, editors.World Health Organization classi fi cation of tumours pathology and genetics of tumours of the lung, pleura, thymus and heart.Lyon: IARC Press; 2004.
58. Travis WD, Brambilla E, Noguchi M, et al.International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classi fi cation of lung adenocarcinoma.J Thorac Oncol.2011;6:244-85.
59. Travis WD, Giroux DJ, Chansky K, et al.The IASLC lung cancer staging project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classi fi cation for lung cancer.J Thorac Oncol.2008;3:1213-23.
60. Tsao AS, Tang XM, Sabloff B, et al.Clinicopathologic characteristics of the EGFR gene mutation in nonsmall cell lung cancer.J Thorac Oncol.2006; 1:231-9.
61. Turke AB, Zejnullahu K, Wu YL, et al.Preexistence and clonal selection of MET ampli fi cation in EGFR mutant NSCLC.Cancer Cell.2010;17:77-88.
62. Weir BA, Woo MS, Getz G, et al.Characterizing the cancer genome in lung adenocarcinoma.Nature.2007; 450:893-8.
63. Yao JC, Hassan M, Phan A, et al.One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States.J Clin Oncol.2008;26:3063-72.
64. Yarden Y, Sliwkowski MX.Untangling the ErbB signalling network.Nat Rev Mol Cell Biol.2001;2:127-37.
65. Yatabe Y, Takahashi T, Mitsudomi T.Epidermal growth factor receptor gene ampli fi cation is acquired in association with tumor progression of EGFR-mutated lung cancer.Cancer Res.2008;68:2106-11.
66. Yu J, Kane S, Wu J, et al.Mutation-speci fi c antibodies for the detection of EGFR mutations in nonsmall-cell lung cancer.Clin Cancer Res.2009;15:3023-8.